UK Wants Early Access Scheme To Remain ‘Relevant And Attractive’ Following Brexit
Proposals Aim To Reduce Burden Associated With Collecting Real-World Data
Executive Summary
The MHRA has drawn up measures to improve regulatory certainty around the UK’s early patient access scheme while reducing regulatory burden in certain areas of its operation.
You may also be interested in...
UK MHRA Aims To Cast Early Access Scheme In New Light
The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.
COVID-19 Redefining Clinical Trial Transparency Expectations & Challenges
A senior Pfizer executive talks about the high regulatory expectations for public disclosure of clinical trial data for Comirnaty, the COVID-19 vaccine it developed in partnership with BioNTech. There were also concerns about re-identification of trial participants as many subjects took to social media to share their experiences with the Comirnaty study.
Care Needed With Plain Language Summaries Of EU Study Results
The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.